Optimizing the sequence of anti-EGFR targeted therapy in EGFR-mutant lung cancer

Similar Items

• Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
  od: Jia, Peilin, i dr.
  Izdano: (2013)
• Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma
  od: Pirazzoli, Valentina, i dr.
  Izdano: (2015)
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation
  od: Takezawa, Ken, i dr.
  Izdano: (2012)
• SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer
  od: Ichihara, Eiki, i dr.
  Izdano: (2017)
• Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
  od: Valentina Pirazzoli, i dr.
  Izdano: (2014-05-01)